The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
A major push to sharpen the future of cancer treatment is underway
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
Highlights Mirvetuximab-based regimen promise
Subscribe To Our Newsletter & Stay Updated
